aCFO.next | R Documentation |
In the aCFO design for phase I trials, the function is used to determine the dose movement based on the toxicity outcomes of the enrolled cohorts.
aCFO.next(target, ays, ans, currdose,
prior.para = list(alp.prior = target, bet.prior = 1 - target),
cutoff.eli = 0.95, early.stop = 0.95)
target |
the target DLT rate. |
ays |
the cumulative numbers of DLTs observed in patients for all dose levels. |
ans |
the cumulative numbers of patients for all dose levels. |
currdose |
the current dose level. |
prior.para |
the prior parameters for a beta distribution, where set as |
cutoff.eli |
the cutoff to eliminate overly toxic doses for safety. We recommend
the default value of |
early.stop |
the threshold value for early stopping. The default value |
The aCFO design is an extension of the CFO design. It integrates dose information from all positions (ranging from the lowest to the highest dose levels) into the decision-making process of the trial. Before assigning the dose level for a new cohort, aCFO compares the evidence from the current dose level with all doses to its left and right. In contrast, the original CFO design makes dose allocation by examining one dose level above and one below the current dose level. Consequently, the aCFO design enhances the utilization of information while maintaining the characteristics of the CFO design (model-free and calibration-free). Additionally, the aCFO design preserves the same early stopping and dose elimination criteria as the CFO design.
The aCFO.next()
function returns a list object comprising the following elements:
target: the target DLT rate.
ays: the cumulative counts of DLTs observed at all dose levels.
ans: the cumulative counts of patients treated at all dose levels.
decision: the decision in the aCFO design, where left
, stay
, and right
represent the
movement directions, and stop
indicates stopping the experiment.
currdose: the current dose level.
nextdose: the recommended dose level for the next cohort. nextdose = 99
indicates that the trial is
terminated due to early stopping.
overtox: the situation regarding which position experiences over-toxicity. The dose level indicated by
overtox
and all the dose levels above experience over-toxicity. overtox = NA
signifies that the
occurrence of over-toxicity did not happen.
toxprob: the expected toxicity probability, Pr(p_k > \phi | x_k, m_k)
, at all dose
levels, where p_k
, x_k
, and m_k
is the dose-limiting toxicity (DLT) rate, the
numbers of observed DLTs, and the numbers of patients at dose level k
. NA
indicates that there
are no patients at the corresponding dose level.
The dose level indicated by overtox
and all the dose levels above experience over-toxicity, and these dose levels will be eliminated.
Jialu Fang, Ninghao Zhang, Wenliang Wang, and Guosheng Yin
Jin H, Yin G (2022). CFO: Calibration-free odds design for phase I/II clinical trials.
Statistical Methods in Medical Research, 31(6), 1051-1066.
Fang J, Yin G (2024). Fractional accumulative calibration‐free odds (f‐aCFO) design for delayed toxicity
in phase I clinical trials. Statistics in Medicine, 43(17), 3210-3226.
## determine the dose level for the next cohort of new patients
ays <- c(0, 0, 1, 0, 0, 0, 0); ans <- c(3, 3, 6, 0, 0, 0, 0)
decision <- aCFO.next(target = 0.2, ays = ays, ans = ans, currdose = 3,
prior.para = list(alp.prior = 0.2, bet.prior = 0.8))
summary(decision)
ays <- c(3, 0, 0, 0, 0, 0, 0); ans <- c(3, 0, 0, 0, 0, 0, 0)
decision <- aCFO.next(target = 0.2, ays = ays, ans = ans, currdose = 1,
prior.para = list(alp.prior = 0.2, bet.prior = 0.8))
summary(decision)
ays <- c(0, 0, 0, 0, 0, 0, 3); ans <- c(3, 3, 3, 3, 3, 3, 3)
decision <- aCFO.next(target = 0.2, ays = ays, ans = ans, currdose = 7,
prior.para = list(alp.prior = 0.2, bet.prior = 0.8))
summary(decision)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.